Labcorp Holdings Inc.
Recent
price
P/E
ratio
div
yld
0.87%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Labcorp Holdings Inc. (NYSE: LH), headquartered in Burlington, North Carolina, and founded in 1971, operates as a global life sciences and healthcare company that provides comprehensive laboratory diagnostics and biopharma drug development services across more than 100 countries, with primary operations in the United States; the company conducts business through two main segments, Diagnostics Laboratories and Biopharma Laboratory Services. The Diagnostics Laboratories segment offers routine clinical testing and specialty/esoteric testing, including over 5,000 tests in areas such as oncology, genetics and genomics, women's health, autoimmune diseases, neurology, HIV genotyping and phenotyping, employment screening, DNA parentage and immigration testing, environmental monitoring, wellness, toxicology, pain management, and medical drug monitoring, delivered via approximately 2,000 patient service centers, more than 6,000 in-office phlebotomists, rapid response laboratories, primary laboratories, specialty laboratories, and 50 at-home tests, processing over 700 million tests annually for patients, physicians, hospitals, health systems, managed care organizations, employers, governments, and consumers. The Biopharma Laboratory Services segment delivers end-to-end drug development, medical device, and diagnostic development support to pharmaceutical, biotechnology, medical device, crop protection, and chemical companies, encompassing early development research, central laboratory services, clinical trial testing, and companion diagnostics, supporting more than 75% of new FDA-approved drugs and therapeutics in 2024. In recent developments, Labcorp completed the acquisition of select oncology and clinical testing assets from BioReference Health in September 2025 for up to $225 million to bolster its oncology leadership; acquired assets of Invitae in August 2024 for $239 million to expand genetic testing capabilities; signed agreements to acquire select assets of Empire City Laboratories and Laboratory Alliance of Central New York in 2025 while progressing the Community Health Systems outreach business acquisition across 13 states; launched new Alzheimer's neurology tests, Labcorp Test Finder tool, and consumer tests via Labcorp OnDemand; invested $268.4 million in acquisitions and partnerships during Q3 2025; and expanded its credit facility to $700 million in January 2025.
Company News
Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential
LH vs. DHR: Which Stock Is the Better Value Option?
Labcorp Prepares to Report Q3 Earnings: What's in the Cards?
Labcorp Declares Quarterly Dividend
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
Labcorp Holdings Inc. $LH Shares Sold by Birch Hill Investment Advisors LLC
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal
Three stocks poised to beat estimates this earnings season
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
Labcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health Test
Here's Why Labcorp Holdings (LH) is a Strong Value Stock
Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026
Is This the Right Time to Add Labcorp Stock to Your Portfolio?
Labcorp (NYSE:LH) Shares Gap Down – Should You Sell?
Critical Survey: HCA Healthcare (NYSE:HCA) and Labcorp (NYSE:LH)
Labcorp: The CMS Selloff Represents An Excellent Opportunity - Strong Buy
Labcorp's Future Driven By Clinical Testing Demand, Despite Impact From Medicare Cuts